Somewhat Favorable News Coverage Somewhat Unlikely to Impact Dicerna Pharmaceuticals (DRNA) Share Price
Media stories about Dicerna Pharmaceuticals (NASDAQ:DRNA) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.6679822744782 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Dicerna Pharmaceuticals Inc (DRNA) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Dicerna Pharmaceuticals (DRNA) Set to Announce Quarterly Earnings on Thursday (americanbankingnews.com)
- Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018 (finance.yahoo.com)
- Dicerna Pharmaceuticals, Inc. (DRNA) stock price moves 135.01% up oppose to an average of last 200 Days – The Stocks News (press release) (thestocksnews.com)
- Dicerna Pharmaceuticals, Inc. (DRNA) : The Stock on Analysts Watch-List – Wall Street Morning (wallstreetmorning.com)
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at $13.45 on Friday. The firm has a market capitalization of $659.97, a price-to-earnings ratio of -3.92 and a beta of 2.18. Dicerna Pharmaceuticals has a 52-week low of $2.52 and a 52-week high of $13.92.
In other news, Director Bain Capital Life Sciences Inv acquired 285,000 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Monday, December 18th. The shares were acquired at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 29.41% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Dicerna Pharmaceuticals (DRNA) Share Price” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-dicerna-pharmaceuticals-drna-share-price/1905885.html.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.